Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer

Philippe Aftimos, Marina Maglakelidze, Andor W. J. M. Glaudemans, Erika Hamilton, Linnea Chap, Elisabeth de Vries, Catharina Willemien Menke-van der Houven van Oordt, Agnes Jager, E. Claire Dees, Massimo Cristofanilli, Mark Pegram, Susanna Ulahannan, Patrick Neven, Iurie Bulat, Ruhi Rai, Wenli Tao, Sarika Jain, Andrew P. Beelen, Jessica A. Sorrentino

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Number of pages1
JournalCancer Research
Issue number4
Publication statusPublished - Feb-2021

Cite this